The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) and (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.

##STR00001##

The present disclosure relates to substituted thiophene carboxamides derivatives of formula (I) and (II), their use for controlling phytopathogenic microorganisms and compositions comprising thereof.

##STR00001##

Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a substituted lactic acid and/or derivative thereof; and which composition further includes an anionic constituent system which boosts the antimicrobial efficacy of the primary lactic acid constituent present; and which compositions feature low irritation, and good antimicrobial efficacy against certain species of bacteria. Treatment processes using the feminine intimate cleansing composition in treatment of the groin area of human females, and vendible products containing the feminine intimate cleansing compositions are also disclosed.

The present invention relates to a herbicidal combination which comprises: a) a herbicide A which is 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl-(1-methylethyl)-amino]sulfonyl]benzamide, b) a herbicide B which is glufosinate or one of its salts, and c) at least one herbicide C different from herbicides A and B which is selected from C.1) herbicides of the group of acetolactate synthase inhibitors which are selected from the group of triazolopyrimidine herbicides, sulfonylamino-carbonyl-triazolinone herbicides and pyrimidinyl(thio) benzoate herbicides, C.2) herbicides of the group of protoporphyrinogen oxidase inhibitors, C.3) herbicides of the group of synthetic auxins, C.4) herbicides of the group of microtubule inhibitors, C.5) herbicides of the group of acetyl-CoA carboxylase inhibitors, C.6) herbicides of the group of photosystem II inhibitors, C.7) herbicides of the group of pigment synthesis inhibitors, and C.8) herbicides of the group of VLCFA inhibitors which are selected from the group of oxyacetamide herbicides and chloroacetamide herbicides.

The present invention relates to a herbicidal combination which comprises: a) a herbicide A which is 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl-(1-methylethyl)-amino]sulfonyl]benzamide, b) a herbicide B which is glufosinate or one of its salts, and c) at least one herbicide C different from herbicides A and B which is selected from C.1) herbicides of the group of acetolactate synthase inhibitors which are selected from the group of triazolopyrimidine herbicides, sulfonylamino-carbonyl-triazolinone herbicides and pyrimidinyl(thio) benzoate herbicides, C.2) herbicides of the group of protoporphyrinogen oxidase inhibitors, C.3) herbicides of the group of synthetic auxins, C.4) herbicides of the group of microtubule inhibitors, C.5) herbicides of the group of acetyl-CoA carboxylase inhibitors, C.6) herbicides of the group of photosystem II inhibitors, C.7) herbicides of the group of pigment synthesis inhibitors, and C.8) herbicides of the group of VLCFA inhibitors which are selected from the group of oxyacetamide herbicides and chloroacetamide herbicides.

Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.

Disclosed are antimicrobial articles and surfaces, as well as methods of making such articles and surfaces.

Disclosed are antimicrobial articles and surfaces, as well as methods of making such articles and surfaces.

This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.

Disclosed herein are methods of treating neurological or psychiatric diseases or disorders using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.